

Supplementary Table. Ongoing trials with checkpoint inhibitors in cHL (clinicaltrials.gov as of 16th of July 2017)

Drug + combination	Phase	Indication	Endpoints	Sponsor	NCT ID
Ipilimumab (anti-CTLA4)					
+ Nivolumab + BV	I	r/r cHL (n=70)	MTD, ORR, CRR, DOR, PFS, OS	NCI	01896999
+ BV and nivolumab Monotherapy	I/Ib	r/r cHL and other hemato- logic malignancies post alloSCT (n=113)	MTD, ORR, PFS, OSNCI		01822509
Nivolumab (anti-PD1)					
+ Ipilimumab	I/II	r/r cHL and other malig- nancies (age 12m-30y, n=352)	MTD, ORR	NCI	02304458
+ Ipilimumab and liri- lumab	I	r/r cHL + NHL + multiple myeloma (n= 375)	MTD, ORR	BMS	01592370
+ Ipilimumab and dara- tumumab					
+ Ipilimumab, daratu- mumab and poma- lidomide Monotherapy	I/Ib	r/r hematological malig- nancies post alloSCT (n=113)	MTD, ORR, PFS, OSNCI		01822509
+ BV	I/II	r/r cHL (n=92)	AEs, CRR, ORR, DOR, PFS	Seattle Genetics	02572167
+ Ibrutinib	II	r/r cHL (n=17)	CRR, DOR, AEs, ORR, PFS	Ohio State	02940301
+ AVD chemotherapy +30Gy IS-RT	II	early-stage unfavorable cHL (n=110)	CRR, TRM, PFS, OS	University of Co- logne	03004833
+ A(B)VD	I	advanced stage cHL <60y, any stage cHL >60y (n=26)	DLT	MSKCC	03033914
+ BV	II	r/r cHL, age 5y to 30y (n=80)	EFS, CRR, ORR, PFS, DOS,	BMS	02927769
+ BV vs. BV alone (ran- domized)	III	r/r cHL ineligible for auto- SCT (n=340)	PFS, CRR, RR, DOR, OS	BMS	03138499
+ ICE chemotherapy	II	r/r cHL (n=43)	CRR, AEs, ORR, PFS, OS	City of Hope	03016871
+ BV	II	r/r cHL consolidation post autoSCT (n=65)	PFS, AEs, OS, ORR	City of Hope	03057795
Pembrolizumab (anti-PD1)					
+ Consolidative 20- 40Gy IS-RT	II	r/r early stage cHL (n=22)	CRR	MSKCC	03179917
+ AFM13	Ib	r/r cHL (n=33)	DLT, ORR,	Affimed/MSD	02665650
vs. BV (randomized)	III	r/r cHL (n=300)	PFS, OS, ORR	MSD	02684292
+ Lenalidomide	I/II	r/r cHL (n=29)	MTD, ORR, CRR, DOR	NYU	02875067
Monotherapy	II	r/r cHL and NHL consolida- tion post autoSCT (n=60)	PFS, OS, ORR	Dana-Farber	02362997
+ ICE chemotherapy	II	r/r cHL (n=40)	CRR, EFS, OS	Northwestern	03077828

Drug + combination	Phase	Indication	Endpoints	Sponsor	NCT ID
+ Vorinostat	I	r/r cHL, NHL (n=60)	AEs, CRR, DOR, ORR, PFS, OS	University City of Hope	03150329
Monotherapy	II	r/r cHL, NHL, MDS, AML post alloSCT (n=26)	AEs, DOR, ORR, CRR, OS	University of Chicago	02981914
Monotherapy	I	HIV-positive r/r cHL and other malignancies (n=39)	AEs, DOR, ORR, PFS, OS	NCI	02595866
Monotherapy	Ib	r/r cHL and other hematologic malignancies (n=222)	AEs, OR, CRR	MSD	01953692
IBI-308 (anti-PD1)					
Monotherapy	II	r/r cHL (n=90)	ORR	Innovent Biologics	03205891
SHR-1210 (anti-PD1)					
Monotherapy	II	r/r cHL (n=60)	ORR	Jiangsu HengRui Medicine	03155425
BGB-A317 (anti-PD1)					
Monotherapy	II	r/r cHL (n=68)	ORR, PFS, DOR, CRR	BeiGene	03209973
Avelumab (anti-PD-L1)					
Monotherapy	Ib	r/r cHL after autoSCT (n=70)	PK, correlative studies, ORR, DOR, PFS	Pfizer	02603419
Atezolizumab (anti-PD-L1)					
Monotherapy	II	r/r cHL (n=57)	PFS	MSKCC	03120676
CK-301 (anti-PD-L1)					
Monotherapy	I	r/r cHL and advanced malignancies (n=80)	AEs, ORR, DOR, PK	Checkpoint Therapeutics	03212404
Durvalumab (anti-PD-L1)					
Monotherapy	I/II	r/r cHL and other lymphomas (n=253)	MTD, AEs, ORR, PFS, OS	Celgene	02733042

PD1: programmed death receptor 1; PD-L1: PD-ligand 1; r/r cHL: relapsed or refractory classical Hodgkin lymphoma; alloSCT: allogeneic stem-cell transplantation; autoSCT: autologous stem-cell transplantation; HIV: human immunodeficiency virus; MTD: maximum tolerated dose; AEs: adverse events; ORR: overall response rate; CRR: complete response rate; DOR: duration of response; PFS: progression-free survival; OS: overall survival; PK: pharmacokinetics; TRM: treatment related morbidity; BMS: Bristol-Myers Squibb; MSD: Merck-Sharp Dohme; MSKCC: Memorial-Sloan Kettering Cancer Center; MDACC: MD Anderson Cancer Center; NCI: National Cancer Institute; NYU: New York University; n: patients to be enrolled; vs.: randomization versus treatment X.